RxDoctor Payments Data

Raul Rios Mollineda, MD

Pulmonary Disease · Bayamon, PRNPI 1790878916

Payments from drug & device makers

$1,845in general payments, 2019–2025

Across 49 payments — averaging $37.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$555
  • GSK$380
  • Genentech USA, Inc.$355
  • Jazz Pharmaceuticals Inc.$157
  • E.r. Squibb & Sons, L.L.C.$119
  • Boehringer Ingelheim$93
  • plus $187 from 7 others

What the payments were for

  • Food & beverage$1,845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,845 in reported general payments places this provider in the 40th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$54,870
Medicare patients
136
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate51$586,567
Trelegy ElliptaFluticasone/Umeclidin/Vilanter371$250,572
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate591$146,634
Breo ElliptaFluticasone/Vilanterol207$89,966
SymbicortBudesonide/Formoterol Fumarate237$57,438
Spiriva RespimatTiotropium Bromide78$42,200
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$31,503
Albuterol Sulfate HfaAlbuterol Sulfate594$26,249
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$24,470
Montelukast Sodium2,413$24,423
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$23,638
Wixela InhubFluticasone Propion/Salmeterol137$19,710
Fluticasone Propionate HfaFluticasone Propionate64$16,474
Atrovent HfaIpratropium Bromide31$14,647
Fluticasone Propionate616$11,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$93$652,404177 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$380$372,041644 claims
AstraZenecaSymbicort, Breztri Aerosphere, Daliresp$555$86,847282 claims
PfizerEliquis, Levoxyl$35$8,84825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →